公开(公告)号：US20240240209A1

公开(公告)日：2024-07-18

申请号：US18556152

申请日：2022-04-20

Applicant: Agency for Science, Technology and Research ,  Institut National De Recherche Pour L' Agriculture, L'Alimentation Et L'Environment ,  Centre National De La Recherche Scientifique ,  Institut National Des Sciences Appliquées De Toulouse

Inventor： Xixian CHEN ,  Congqiang ZHANG ,  Rehka T ,  Sudha SHUKAL ,  Derek SMITH ,  Isabelle ANDRÉ ,  Esque JEREMY

IPC: C12P7/26 ,  C12N9/10 ,  C12N9/78 ,  C12N15/52 ,  C12N15/70 ,  C12P41/00

CPC classification number: C12P7/26 ,  C12N9/1007 ,  C12N9/78 ,  C12N15/52 ,  C12N15/70 ,  C12P41/00 ,  C12Y201/01 ,  C12Y201/01067 ,  C12Y305/04028 ,  C12N2800/101

Abstract: Synthesis of enantiopure cis-α-irone from a renewable carbon source Disclosed herein are natural and synthetic enzymes capable of performing a method of producing cis-α-irone. The method comprises providing an enzyme capable of converting psi-ionone to cis-α-irone; and contacting the enzyme and psi-ionone under suitable conditions to produce cis-α-irone. The enzyme may be a methyltransferase from Streptomyces albireticuli (SaMT), a promiscuous bifunctional methyltransferase/cyclase (pMT1) enzyme from Streptomyces, or a modified pMT1 enzyme with at least one substitution. The enzymes allow the in-vivo and in-vitro production of cis-α-irone including the use of glucose as feedstock for the biotransformation into cis-α-irone.

公开(公告)号：US20240002892A1

公开(公告)日：2024-01-04

申请号：US18035281

申请日：2021-09-09

Applicant: SHENZHEN READLINE BIOTECH CO., LTD.

Inventor： Mingru HUANG ,  Junfeng PAN ,  Jian LIU

IPC: C12P13/04 ,  C12N9/10

CPC classification number: C12P13/04 ,  C12N9/13 ,  C12N9/1007 ,  C12Y201/01044 ,  C12Y201/01067 ,  C12Y208/01001

Abstract: A compound enzyme, comprising L-histidine methylase, halogen methyltransferase and trimethylhistidine sulfurylase. L-histidine is catalyzed by L-histidine methylase and halogen methyltransferase to obtain trimethylhistidine, and then is catalyzed by trimethylhistidine sulfurase to obtain the L-ergothioneine. The method can realize conversion from L-histidine to L-ergothioneine only in two steps. Moreover, SAM enzyme is regenerated, such that the usage amount of the SAM enzyme is greatly reduced. Therefore, the method greatly reduces the raw material cost. Moreover, the method is high in reaction concentration (about 30 g/L), simple in process and good in industrial production prospect.

公开(公告)号：US20110300535A1

公开(公告)日：2011-12-08

申请号：US12672620

申请日：2008-08-07

Applicant: Rebecca Lee Roberts ,  Richard Blair Gearry ,  Murray Lindsay Barclay ,  Martin Alexander Kennedy

Inventor： Rebecca Lee Roberts ,  Richard Blair Gearry ,  Murray Lindsay Barclay ,  Martin Alexander Kennedy

IPC: C12Q1/68 ,  C07H21/04

CPC classification number: C12Q1/6883 ,  C12N9/1007 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y201/01067

Abstract: The invention relates to methods and kits for identifying individuals at risk of thiopurine drug intolerance based on detecting the presence of mutations in the TPMT gene promoter associated with thiopurine drug resistance or intolerance.

Abstract translation: 本发明涉及用于基于检测与硫嘌呤耐药性或不耐受性相关的TPMT基因启动子中存在突变而鉴定硫嘌呤药物不耐受风险的个体的方法和试剂盒。

公开(公告)号：US5856095A

公开(公告)日：1999-01-05

申请号：US514921

申请日：1995-08-14

Applicant: William E. Evans ,  Eugene Y. Krynetski

Inventor： William E. Evans ,  Eugene Y. Krynetski

IPC: C12N9/10 ,  C12Q1/68 ,  C07H21/04 ,  C12P19/34

CPC classification number: C12N9/1007 ,  C12Q1/6886 ,  C12Y201/01067 ,  C12Q2600/142 ,  C12Q2600/154 ,  Y10S435/81

Abstract: Mutants of thiopurine S-methyltransferase (TPMT) are described. TPMTA mutant has a point mutation at cDNA position 238 (G.sup.238 .fwdarw.C), and TPMTB involves two nucleotide transitions at cDNA positions 460 (G.sup.460 .fwdarw.A) and 719 (A.sup.719 .fwdarw.G). TPMTB is the predominant mutant allele associated with human TPMT-deficiency which can cause potentially fatal toxicity when patients are treated with mercaptopurine, azathioprine, or thioguanine. The mutant alleles as well as PCR fragments, mutant proteins and antibodies therefor, together with kits and methods for assaying the TPMT genotype of individual patients are disclosed.

Abstract translation: 描述了硫嘌呤S-甲基转移酶（TPMT）的突变体。 TPMTA突变体在cDNA位置238（G238-> C）处具有点突变，并且TPMTB涉及cDNA位置460（G460→A）和719（A719→G）两个核苷酸转换。 TPMTB是与人类TPMT缺乏相关的主要突变体等位基因，当患者用巯嘌呤，硫唑嘌呤或硫鸟嘌呤治疗时，可引起潜在的致命毒性。 公开了突变等位基因以及PCR片段，突变蛋白和其抗体，以及用于测定个体患者的TPMT基因型的试剂盒和方法。